Factoring weight for weight, the dose of AAV9 vector administered to the Hpse2 mutant mice in the current study is of a similar order of magnitude as those used to treat babies with spinal muscular atrophy (Mendell et al., 2017). This evidence concerns the gene HPSE2 and spinal muscular atrophy.